Literature DB >> 25568654

Screening, diagnosis and treatment of osteoporosis: a brief review.

Roberto Bernabei1, Anna Maria Martone1, Elena Ortolani1, Francesco Landi1, Emanuele Marzetti1.   

Abstract

Osteoporosis is a highly prevalent condition characterized by decreases in bone mass and microarchitectural alterations. Bone fractures, especially of the hip and vertebrae, are the most burdensome complications of osteoporosis, being associated with high risk of disability, institutionalization and mortality. The detection of osteoporosis relies on the quantification of bone mineral density via imaging techniques such as dual-energy X-ray absorptiometry. However, therapeutic decision-making should be based on a comprehensive fracture risk assessment, which may be obtained through validated algorithms. Once the decision of treating has been taken, non-pharmacological strategies should be implemented together with the prescription of anti-osteoporotic agents. Numerous drugs are currently available to treat osteoporosis and the choice of a specific compound should be guided by efficacy and safety considerations. The present review provides a concise synopsis of the current evidence in the management of osteoporosis, from screening to drug prescription. Novel anti-osteoporotic agents are also briefly presented.

Entities:  

Keywords:  bisphosphonates; denosumab; strontium ranelate; teriparatide; vitamin D

Year:  2014        PMID: 25568654      PMCID: PMC4269144     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  85 in total

Review 1.  Bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Eur Spine J       Date:  2003-09-16       Impact factor: 3.134

Review 2.  [Update on vitamin D and evaluation of vitamin D status].

Authors:  J-C Souberbielle; D Prié; M Courbebaisse; G Friedlander; P Houillier; G Maruani; E Cavalier; C Cormier
Journal:  Ann Endocrinol (Paris)       Date:  2008-09-18       Impact factor: 2.478

3.  Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.

Authors:  J D Wark; W Bensen; C Recknor; O Ryabitseva; J Chiodo; P Mesenbrink; T J de Villiers
Journal:  Osteoporos Int       Date:  2011-02-19       Impact factor: 4.507

4.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Authors:  Silvana Martino; Jane A Cauley; Elizabeth Barrett-Connor; Trevor J Powles; John Mershon; Damon Disch; Roberta J Secrest; Steven R Cummings
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

5.  Raloxifene: results from the MORE study.

Authors:  D Agnusdei; N Iori
Journal:  J Musculoskelet Neuronal Interact       Date:  2000-12       Impact factor: 2.041

6.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

7.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

8.  Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.

Authors:  Deborah Grady; Bruce Ettinger; Elena Moscarelli; Leo Plouffe; Somnath Sarkar; Angelina Ciaccia; Steven Cummings
Journal:  Obstet Gynecol       Date:  2004-10       Impact factor: 7.661

9.  Use of alendronate and risk of incident atrial fibrillation in women.

Authors:  Susan R Heckbert; Guo Li; Steven R Cummings; Nicholas L Smith; Bruce M Psaty
Journal:  Arch Intern Med       Date:  2008-04-28

10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; E V McCloskey; H Johansson; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-10-19       Impact factor: 4.507

View more
  35 in total

1.  The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study.

Authors:  Alexis Ogdie; Lauren Harter; Daniel Shin; Joshua Baker; Junko Takeshita; Hyon K Choi; Thorvardur Jon Love; Joel M Gelfand
Journal:  Ann Rheum Dis       Date:  2017-01-16       Impact factor: 19.103

2.  Osteoblastic NF-κB pathway is involved in 1α, 25(OH)2D3-induced osteoclast-like cells formation in vitro.

Authors:  Lin Cong; Chaoyi Zhang; Guanjun Tu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  The effect of PDE5 inhibitors on bone and oxidative damage in ovariectomy-induced osteoporosis.

Authors:  Hamit H Alp; Zübeyir Huyut; Serkan Yildirim; Yıldıray Başbugan; Levent Ediz; Mehmet R Şekeroğlu
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-11

Review 4.  Pulse-Echo Measurements of Bone Tissues. Techniques and Clinical Results at the Spine and Femur.

Authors:  Delia Ciardo; Paola Pisani; Francesco Conversano; Sergio Casciaro
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Influence of systemic strontium ranelate on the progression and as adjunctive therapy for the nonsurgical treatment of experimental periodontitis.

Authors:  David-Jonathan-Rodrigues Gusman; Henrique-Rinaldi Matheus; Breno-Edson-Sendão Alves; Edilson Ervolino; Nathália-Januario de Araujo; Bianca-Rafaeli Piovezan; Luiz-Guilherme Fiorin; Juliano-Milanezi de Almeida
Journal:  J Clin Exp Dent       Date:  2021-12-01

6.  Lifestyle factors influencing bone health in young adult women in Saudi Arabia.

Authors:  Lina F Hammad; Nada Benajiba
Journal:  Afr Health Sci       Date:  2017-06       Impact factor: 0.927

Review 7.  New perspectives in echographic diagnosis of osteoporosis on hip and spine.

Authors:  Sergio Casciaro; Francesco Conversano; Paola Pisani; Maurizio Muratore
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

Review 8.  The role of TRPV channels in osteoporosis.

Authors:  Na Liu; Weiwei Lu; Xiaolin Dai; Xiaowen Qu; Chongtao Zhu
Journal:  Mol Biol Rep       Date:  2021-10-25       Impact factor: 2.316

Review 9.  Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.

Authors:  Arti D Shah; Dolores Shoback; E Michael Lewiecki
Journal:  Int J Womens Health       Date:  2015-06-02

10.  Nutrition and Osteoporosis: Preliminary data of Campania Region of European PERsonalised ICT Supported Service for Independent Living and Active Ageing.

Authors:  L Vuolo; L Barrea; M C Savanelli; S Savastano; M Rubino; E Scarano; M Soprano; M Illario; A Colao; C Di Somma
Journal:  Transl Med UniSa       Date:  2016-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.